RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/8759757http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/8759757http://www.w3.org/2000/01/rdf-schema#comment"Mast cells are known to accumulate at sites of inflammation, however, the chemotaxins involved are undefined. Since most natural leukocyte secretagogues also induce cell migration, and since the anaphylatoxins C3a and C5a are mast cell secretagogues, we hypothesized that both C3a and C5a are also mast cell chemotaxins. Here we report that C3a and C5a are, in fact, potent chemotaxins for the human mast cell line HMC-1. The optimal concentrations, half-maximal effective concentrations (a measure of agonist potency) and the efficacy (response at the optimal concentration) compared with medium control were, for C3a: 10 nM, 0.5 nM, and 256%, respectively; for C5a: 1 nM, 10 pM and 145%. Chemotaxis of HMC-1 cells to both C3a and C5a was blocked by pertussis toxin, suggesting that Gi-coupled receptors are involved in signal transduction. C3a and C5a also induced transient pertussis toxin-inhibitable increases in [Ca2+]i (ED50 = 1 nM for both) that could be homologously but not heterologously desensitized, suggesting that the receptors for C3a and C5a are distinct. These results make C3a the most effective mast cell chemotaxin identified to date. The chemotactic potency described here for C3a is also 100-to 1000-fold greater than for all of its previously described cellular actions. Direct chemoattraction of mast cells by C3a and C5a may help explain the rapid accumulation of mast cells at sites of inflammation."xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/author"Murphy P.M."xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/author"Tiffany H.L."xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/author"Metcalfe D.D."xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/author"Hammer C.H."xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/author"Nilsson K."xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/author"Nilsson G."xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/author"Siegbahn A."xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/author"Johnell M."xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/date"1996"xsd:gYear
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/name"J Immunol"xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/pages"1693-1698"xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/title"C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway."xsd:string
http://purl.uniprot.org/citations/8759757http://purl.uniprot.org/core/volume"157"xsd:string
http://purl.uniprot.org/citations/8759757http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/8759757
http://purl.uniprot.org/citations/8759757http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/8759757
http://purl.uniprot.org/uniprot/P01031#attribution-88053816C526AC1DC330387B9DD39A62http://purl.uniprot.org/core/sourcehttp://purl.uniprot.org/citations/8759757